
Summit Shares Fall as FDA Rejects Lung Cancer Drug
Shares of Summit Therapeutics dropped 14 percent after the US FDA declined to approve its experimental lung cancer drug ivonescimab. The regulator cited a failure to achieve a significant overall survival benefit in a late-stage study.
Xurve View
Insights:
Xurve View

Summit Therapeutics Inc shares fell 14% to $12.16 during Monday morning trading after the United States Food and Drug Administration declined to approve its experimental lung cancer drug ivonescimab. The regulatory setback arrives after the agency cited the treatment's failure to achieve statistical significance for overall survival in a late-stage trial. The decision carries broad consequences across the pharmaceutical sector.







